Please use this identifier to cite or link to this item: https://doi.org/10.3390/ijms17030291
DC FieldValue
dc.titleRNA interference in the age of CRISPR: Will CRISPR interfere with RNAI?
dc.contributor.authorUnniyampurath, U
dc.contributor.authorPilankatta, R
dc.contributor.authorKrishnan, M.N
dc.date.accessioned2020-11-10T08:00:36Z
dc.date.available2020-11-10T08:00:36Z
dc.date.issued2016
dc.identifier.citationUnniyampurath, U, Pilankatta, R, Krishnan, M.N (2016). RNA interference in the age of CRISPR: Will CRISPR interfere with RNAI?. International Journal of Molecular Sciences 17 (3) : 291. ScholarBank@NUS Repository. https://doi.org/10.3390/ijms17030291
dc.identifier.issn16616596
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/183348
dc.description.abstractThe recent emergence of multiple technologies for modifying gene structure has revolutionized mammalian biomedical research and enhanced the promises of gene therapy. Over the past decade, RNA interference (RNAi) based technologies widely dominated various research applications involving experimental modulation of gene expression at the post-transcriptional level. Recently, a new gene editing technology, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and the CRISPR-associated protein 9 (Cas9) (CRISPR/Cas9) system, has received unprecedented acceptance in the scientific community for a variety of genetic applications. Unlike RNAi, the CRISPR/Cas9 system is bestowed with the ability to introduce heritable precision insertions and deletions in the eukaryotic genome. The combination of popularity and superior capabilities of CRISPR/Cas9 system raises the possibility that this technology may occupy the roles currently served by RNAi and may even make RNAi obsolete. We performed a comparative analysis of the technical aspects and applications of the CRISPR/Cas9 system and RNAi in mammalian systems, with the purpose of charting out a predictive picture on whether the CRISPR/Cas9 system will eclipse the existence and future of RNAi. The conclusion drawn from this analysis is that RNAi will still occupy specific domains of biomedical research and clinical applications, under the current state of development of these technologies. However, further improvements in CRISPR/Cas9 based technology may ultimately enable it to dominate RNAi in the long term. @ 2016 by the authors; licensee MDPI, Basel, Switzerland.
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceUnpaywall 20201031
dc.subjectclustered regularly interspaced short palindromic repeat
dc.subjectgenome
dc.subjectindel mutation
dc.subjectmammal
dc.subjectmedical research
dc.subjectRNA interference
dc.subjectanimal
dc.subjectCRISPR Cas system
dc.subjectgene targeting
dc.subjectgenetics
dc.subjecthuman
dc.subjectprocedures
dc.subjecttrends
dc.subjectsmall interfering RNA
dc.subjectAnimals
dc.subjectCRISPR-Cas Systems
dc.subjectGene Targeting
dc.subjectHumans
dc.subjectRNA Interference
dc.subjectRNA, Small Interfering
dc.typeReview
dc.contributor.departmentDUKE-NUS MEDICAL SCHOOL
dc.description.doi10.3390/ijms17030291
dc.description.sourcetitleInternational Journal of Molecular Sciences
dc.description.volume17
dc.description.issue3
dc.description.page291
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_3390_ijms17030291.pdf394.96 kBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

40
checked on Jan 14, 2022

WEB OF SCIENCETM
Citations

36
checked on Oct 7, 2021

Page view(s)

101
checked on Jan 20, 2022

Download(s)

1
checked on Jan 20, 2022

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons